TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03603977
Drug: Lpv/r+3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
Study: NCT02744482
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: risedrante placebo tablet (75 mg)
Study: NCT00738062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT05123976
Drug: Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
Study: NCT00550862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00844480
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid, 5mg, iv
Study: NCT00844480
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv
Study: NCT01611584
Drug: ALA-induced Fluorescence
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA Dose- 20 mg/kg
Study: NCT00696241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
Study: NCT04060199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01005888
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00160134
Drug: SLV320
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04631107
Drug: AD109 dose1- A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT02013388
Drug: N91115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO daily for 14 days
Study: NCT02013388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO daily for 14 days
Study: NCT02013388
Drug: N91115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO only on Day 1
Study: NCT02013388
Drug: Placebo-Day 1 only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO- only on Day 1 (single dosed to match single dose treatments)
Study: NCT00542048
Drug: EndoTAG®-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoTAG®-1 22 mg/m² twice weekly
Study: NCT00978354
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion 0.9% normal saline placebo control
Study: NCT04631107
Drug: AD109 dose2- B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT04631107
Drug: Placebo- C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT00971035
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeating dose
Study: NCT00718484
Drug: Palifosfamide Tris and Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
Study: NCT00718484
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
Study: NCT00376324
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
Study: NCT01455181
Drug: NPSP558
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50, 75, 100 μg
Study: NCT00171639
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01421095
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will recieve recombinant FSH (150 IU) intravenously
Study: NCT02799472
Drug: GSK3196165
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study: NCT02799472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
Study: NCT02799472
Drug: Folic (or folinic) acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, tablet or liquid and will be administered orally.
Study: NCT00871442
Drug: PCEA solution (bupivacaine and fentanyl)
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
Study: NCT02140983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication
Study: NCT01068626
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg once daily
Study: NCT01068626
Drug: Placebo for rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00737893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
Study: NCT01046851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a manner similar to the active comparator
Study: NCT03785509
Drug: DAPT, Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
Study: NCT03094442
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
Study: NCT03451916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
Study: NCT02167217
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
Study: NCT00077116
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02482324
Drug: ALZT-OP1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mast cell stabilizer
Study: NCT02482324
Drug: ALZT-OP1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-inflammatory
Study: NCT04501289
Drug: Pritchard regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive loading dose as 4g of 20% MgSO4 I.V. over 10 minutes, followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for patients with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for cohorts with eclampsia.
Study: NCT02834559
Drug: 5-fluorouracil and low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
Study: NCT02834559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
Study: NCT00348426
Drug: Botulinum AntiToxin
Normalized name: Botulinum antitoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002941
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03427268
Drug: PM060184
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle).
Study: NCT03950141
Drug: Apatinib and S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
Study: NCT00933582
Drug: JNJ-39439335; Placebo; Naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03535194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00334191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02226926
Drug: Persantin Retard
Normalized name: Persantin Retard
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02226926
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02785874
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
Study: NCT02397291
Drug: Myoinositol
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
Study: NCT02397291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01145807
Drug: TDT067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
Study: NCT01145807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
Study: NCT01145807
Drug: Transfersome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
Study: NCT02358304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02732405
Drug: MK5172 /MK8742
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
Study: NCT00118261
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study: NCT00118261
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study: NCT01472939
Drug: Placebo + PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo t.i.d. taken in addition to a PPI
Study: NCT01282801
Drug: Effexor® XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Extended-Release Capsule
Study: NCT03615781
Drug: Four week's arm - drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
Study: NCT00187915
Drug: Mycophenolate mofetil + Tacrolimus
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target MPA exposure to 30-60 mg/L/h during first month post-transplant
Study: NCT00187915
Drug: Mycophenolate mofetil + Cyclosporin
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target MPA exposure to 30-60 mg/L/h during first month post-transplant
Study: NCT00552032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
Study: NCT01378910
Drug: Unique
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [UNIQUE Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
Study: NCT02124148
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT02124148
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO
Study: NCT02124148
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT03002038
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
Study: NCT03351738
Drug: MEDI5884
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
Study: NCT03351738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
Study: NCT01049854
Drug: Full Intensity
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
Study: NCT04439825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution (preservative free)
Study: NCT00896428
Drug: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet morning and evening for 12 months
Study: NCT04309929
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
Study: NCT00249795
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (tablets) once daily
Study: NCT02566798
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7
Study: NCT00943371
Drug: MK6349
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
Study: NCT00943371
Drug: Comparator: Placebo to MK6349
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
Study: NCT01954368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
Study: NCT01954368
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
Study: NCT03635489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
Study: NCT04787510
Drug: low molecular weight Heparin as standard of care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STANDARD OF CARE
Study: NCT02766621
Drug: Placebo injection SC/IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Placebo to different doses of PF-06823859
Study: NCT00092339
Drug: Comparator: valdecoxib, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01986101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01986101
Drug: SM-13496
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
Study: NCT01986101
Drug: SM-13496
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
Study: NCT01358578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
Study: NCT01693692
Drug: TD-9855 Group 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01693692
Drug: TD-9855 Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01693692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00693576
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg simvastatin daily
Study: NCT02400645
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
Study: NCT00405639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be used for placebo.
Study: NCT02402296
Drug: β-1,3/1,6-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
Study: NCT02459158
Drug: ME1100 inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Study: NCT02459158
Drug: ME1100 inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Study: NCT01211483
Drug: U3-1287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid 70 mg/mL for IV infusion at high dose or low dose
Study: NCT01211483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid matching U3-1287 for IV infusion
Study: NCT01276691
Drug: 81 mg enteric coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
Study: NCT00913185
Drug: Acne Free, Proactiv
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01743794
Drug: Saline solution 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
Study: NCT00006033
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes